Abstract:Enterovirus A71 (EV-A71) is an important causative agent of hand-foot-and-mouth disease (HFMD) associated with enormous healthcare and socioeconomic burden. Although a range of studies about EV-A71 pathogenesis have been well described, the underlying molecular mechanism in terms of innate immune response is still not fully understood, especially the roles of TANK-binding kinase 1 (TBK1) and interferon-regulatory factor 3 (IRF3). Here, we applied TBK1 inhibitor and IRF3 agonist, for the first time, to evaluate the antiviral activities of TBK1 and IRF3 in vivo . We found that, through regulating EV-A71-induced type I interferon (IFN) response, IRF3 agonist effectively alleviated EV-A71-induced illness, while TBK1 inhibitor aggravated disease progression. In addition, EV-A71 replication was suppressed in EVA-71-infected mice administrated with IRF3 agonist. On the other hand, more severe pathological alterations of neuronal degeneration, muscle fiber breaks, fractured or fused alveolar walls, and diffuse congestion occurred in EVA-71-infected mice treated with TBK1 inhibitor administration. Furthermore, we determined the concentrations of interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), IL-1β, monocyte chemotactic protein-1 (MCP-1), and IL-10 in both lungs and brains of mice and found that TBK1 inhibitor promoted EV-A71-induced inflammatory response, while IRF3 agonist alleviated it, which was consistent with clinical manifestations and pathological alterations. Collectively, our findings suggest that TBK1 and IRF3 are potential therapeutic targets in EV-A71-induced illness. EV-A71 is an important causative agent of HFMD. There is currently no specific antiviral agent to treat HFMD and the related severe complications. The underlying molecular mechanism controlling host innate immunity after EV-A71 infection is still not fully understood, especially the roles of TBK1 and IRF3. Here, we applied TBK1 inhibitor (TBK1/IKKε-IN-2) and IRF3 agonist (KIN1148) to evaluate the antiviral activities of TBK1 and IRF3 in vivo . We found through regulating EV-A71-induced type I IFN response, IRF3 agonist effectively alleviated EV-A71-induced illness, while TBK1 inhibitor aggravated disease progression. More severe pathological alterations of neuronal degeneration, muscle fiber breaks, fractured or fused alveolar walls and diffuse congestion occurred in EVA-71-infected mice with TBK1 inhibitor treatment, while no obvious pathological change occurred in EVA-71-infected mice with IRF3 agonist treatment and control mice. Furthermore, TBK1 inhibitor promoted EV-A71-induced inflammatory response, while IRF3 agonist alleviated it. Our findings suggest that TBK1 and IRF3 are potential therapeutic targets in EV-A71-induced illness for the development of new antiviral agents and therapeutic strategies.

Tia-1 and Tiar Interact with 5 '-Utr of Enterovirus 71 Genome and Facilitate Viral Replication

Increased frequency of circulating follicular helper T cells in children with hand, foot, and mouth disease caused by enterovirus 71 infection.

The Golgi Protein ACBD3 Facilitates Enterovirus 71 Replication by Interacting with 3A

Enterovirus 3A facilitates viral replication by promoting PI4KB-ACBD3 interaction.

Enterovirus 3a Facilitates Viral Replication By Promoting Phosphatidylinositol 4-Kinase Iii Beta-Acbd3 Interaction

PolyC-Binding Protein 1 Interacts with 5′-Untranslated Region of Enterovirus 71 RNA in Membrane-Associated Complex to Facilitate Viral Replication

Early Growth Response-1 Facilitates Enterovirus 71 Replication by Direct Binding to the Viral Genome RNA.

Sirt1 Inhibits Ev71 Genome Replication and Rna Translation by Interfering with the Viral Polymerase and 5 ' Utr Rna

N -Acetyltransferase 8 Promotes Viral Replication by Increasing the Stability of Enterovirus 71 Nonstructural Proteins

TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases

MOV10 interacts with Enterovirus 71 genomic 5'UTR and modulates viral replication.

Heat shock protein 70 as a supplementary receptor facilitates enterovirus 71 infections in vitro

TLR4 signalling: the key to controlling EV71 replication and inflammatory response

The class III phosphatidylinositol 3-kinase VPS34 supports EV71 replication by promoting viral replication organelle formation

EV71 5'UTR interacts with 3D protein affecting replication through the AKT-mTOR pathway

Enterovirus 71 non-structural protein 3A hijacks vacuolar protein sorting 25 to boost exosome biogenesis to facilitate viral replication

Tribbles pseudokinase 3 promotes enterovirus A71 infection via dual mechanisms

Enterovirus-A71 exploits RAB11 to recruit chaperones for virus morphogenesis

The Untranslated Regions of EV-A71 Contribute to Its Pathogenicity and Virulence.

HRS Plays an Important Role for TLR7 Signaling to Orchestrate Inflammation and Innate Immunity Upon EV71 Infection

Enterovirus 71 Represses Interleukin Enhancer-Binding Factor 2 Production and Nucleus Translocation to Antagonize ILF2 Antiviral Effects